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Abstract
BACKGROUND—Historically, stage I rectal cancer was treated with total mesorectal excision. 
However, there has been growing use of local excision, with and without adjuvant therapy to treat 
these early rectal cancers. Little is known about how patients and providers choose amongst the 
various treatment approaches.
OBJECTIVE—To identify patient roles, preferences and expectations as they relate to treatment 
decision-making for patients with stage I rectal cancer.
DESIGN AND SETTINGS—Geographically diverse population and health-system based cohort 
study.
PATIENTS—154 adults with newly diagnosed and surgically treated stage I rectal cancer between 
2003–2005.
MAIN OUTCOME MEASURES—We compared patients by surgical treatment groups: (1) total 
mesorectal excision and (2) local excision. Clinical, sociodemographic, and health-system factors 
were assessed for association with patient decision-making preferences and expectations.
RESULTS—80% of total mesorectal excision patients vs. 63% of local excision patients expected 
that surgery would be curative, p=0.04. The total mesorectal excision group was less likely to 
report that radiation would cure their cancer compared to the local excision group (27% vs 63%, 
p=0.004).
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When asked about preferred role in decision making, 28% of total mesorectal excision patients 
preferred patient-controlled decision making compared with 48% of local excision patients, 
p=0.046. However, with regard to the treatment actually received, 38% of the total mesorectal 
excision group reported making their own surgical decision compared to 25% of the local excision 
group, p=0.18.
LIMITATIONS—Limited sample size.
CONCLUSIONS—Patients’ preferred decision-making role did not match the actual decision-
making process. Future efforts should focus on bridging the gap between the decision-making 
process and patients’ preferences of various treatment approaches. This will be particularly 
important as newer innovative procedures play a more prominent role in the rectal cancer 
treatment paradigm.
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rectal cancer; local excision; treatment decision-making
INTRODUCTION
The use of transanal local excision (LE) in the treatment of rectal cancer is increasing.1 
While this trend is appropriate for some patients with low risk tumors, LE alone leads to 
inferior oncologic outcomes in patients with higher risk tumors.2,3 Reasons for the increase 
in LE have not previously been explored.
Total mesorectal excision (TME) alone has been and remains the standard of care for Stage I 
Rectal Cancer and provides excellent oncologic outcomes with >90% overall survival.4 
However, other factors besides oncologic outcomes may influence decision making 
regarding treatment. Presumably, transanal operations are chosen for their lower operative 
morbidity and potential for improved quality of life.
LE is believed to have less impact on quality of life, with less possibility of permanent 
colostomy and less potential for short- and long-term bowel, bladder, and sexual 
dysfunction.5 However, little is known about the decision-making process with various 
treatment approaches.
Prior studies have found certain patient attributes are associated with higher participation in 
decision making for cancer care, such as younger age, better education, and better health.6–8 
Patients who are younger and less educated, or patients who see higher-volume surgeons are 
less likely to have their actual roles match their preferred roles.9 Much of what is known 
comes from studies examining surgical decision making in breast cancer.9–11 To date, no 
study has investigated the surgical decision-making process for rectal cancer, a condition 
needing similar considerations of mortality and morbidity trade-off. Data from the Cancer 
Care Outcomes Research and Surveillance (CanCORS) study, a geographically 
representative study of patients with recently diagnosed rectal cancer, provide an opportunity 
to gain insight into patients’ roles, preferences, and expectations with regard to their rectal 
cancer care. We hypothesized LE patients would play a more active role in the decision-
making process than TME patients, however LE patients would expect a surgical cure less 
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frequently. Additionally, we hypothesized older age and higher comorbidity status would be 
a negative predictor of active decision-making in treatment.
METHODS
Study population and design
CanCORS is a geographically diverse population and health-system based cohort study 
including 4,713 adults age 21 or older with newly diagnosed, pathologically confirmed 
invasive colorectal cancer recruited between 2003–2005. Patients were recruited from four 
geographically based cancer registries in Northern California, Los Angeles County, North 
Carolina and Alabama, from five large health maintenance organizations (HMOs) that are 
part of the Cancer Research Network, and from five Veterans Affairs (VA) hospitals. A 
recent study by Catalano et al. demonstrated that the CanCORS Consortium was successful 
in enrolling a demographically representative sample within the CanCORS regions with a 
response rate of 53.2%.12
As previously described,12 eligible patients from these sites were contacted approximately 4 
months after cancer diagnosis and asked to participate in a telephone survey. Study 
participants responded within 1–12 months; the mean response time was 4 months after 
meeting initial eligibility criteria. No time limitation was allotted for survey response. 
Interviews included questions about sociodemographic information (age, sex, education, 
race, marital status, and health insurance status), treatments received, providers visited, and 
goals, beliefs and preferences with regard to treatment options.13
The CanCORS medical record abstraction (MRA) database contains detailed information on 
tumor characteristics and the acute treatment phase, including types of providers visited, 
staging procedures, and surgery, chemotherapy and radiotherapy regimens.12–14 Medical 
record information was also used to assign American Joint Committee on Cancer (AJCC) 
collaborative stage,15 and to determine Adult Comorbidity Evaluation–27 (ACE-27)16 
comorbidity indicators.
Each patient who discussed surgery, radiation, or chemotherapy with a physician was asked 
to report his or her actual role, and preferred role in the decision by using a modified version 
of the validated Control Preference Scale,17 designed to be administered by telephone. For 
actual and preferred roles, the first two responses were categorized as patient-controlled, the 
third was considered patient-physician shared, and the last two were categorized as 
physician-controlled decision making. Figure 1 and 2 provide the response options for these 
survey questions. In all analyses, actual and preferred roles were categorized as patient-
controlled (responses 1 or 2), shared (response 3), or physician-controlled roles (responses 4 
or 5), as described previously.9,18
To identify current depression, a score of six or more symptoms on the eight-item Center for 
Epidemiological Studies-Depression Scale (CES-D) was used.19
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Data Analysis
The sample consisted of patients with stage I adenocarcinoma of the rectum. Stage was 
based on a hierarchy of best available evidence with Collaborative Stage (calculated AJCC 
stage based on medical record abstracted tumor size, extension, lymph nodes and 
metastases) at the top of the hierarchy.
Patients were divided into two groups based on surgical treatment: (1) local excision (LE) 
and (2) total mesorectal excision (TME). All individuals with stage I rectal adenocarcinoma 
(n=157) were initially included. We excluded three individuals because they underwent a 
fulguration procedure only. The main dependent variables were: (1) the patient role in 
treatment decision-making; (2) patient preferences; and (3) patient expectations regarding 
treatment. Clinical, sociodemographic, and health-system factors were assessed for 
association with patient decision-making, preference, and expectations.
Student’s t-test, chi-square, and Fisher’s exact tests were used to compare the groups on key 
variables obtained from the CanCORS survey and MRA database. Fisher’s exact tests were 
used when sample size was less than five. Multivariate analysis was not used to examine 
patient characteristics associated by surgical treatment due to the small sample size. All 
statistical analysis was performed in SAS v9.3 (Cary, NC). Institutional review board 
exemption was obtained from the University of North Carolina Institutional Review Board.
RESULTS
A total of 154 patients met the inclusion criteria. There were 122 patients who underwent 
TME and 32 patients who were treated with LE for stage I rectal cancer. 24% of TME 
patients and 31% of LE patients received either neoadjuvant or adjuvant chemoradiotherapy.
The characteristics of the two study groups are displayed in Table 1. Compared to the TME 
group, the LE group was more likely to be white, have moderate/severe comorbidities, and 
have a body mass index ≥ 30. Nonetheless, both groups had a similar self-reported health 
rating at the time of diagnosis.
The characteristics of the study population by actual decision-making roles are displayed in 
Table 2. Patients’ actual role in surgical decision-making was unavailable for 32 patients, 
19% (23) TME vs. 28% (9) LE patients, p-value 0.25. Compared to patients <65, a nearly 
significantly smaller percentage of older patients (≥65 years) reported that they made 
decisions independently (33% vs. 50%); conversely, a larger percentage of older patients 
reported relying on physicians to control the decision-making (10% vs. 3%) regarding their 
surgical care (p= 0.08). Also, a larger percentage of individuals with higher education to 
reported making patient-controlled decisions, but the difference did not reach statistical 
significance (48% vs. 33%, p= 0.26).
Patients’ role, beliefs regarding treatment, and treatment preferences are displayed by 
surgery type in Table 3. For both groups, preferences regarding goals of treatment were 
similar; equal numbers wanted treatment that extends life as much as possible as compared 
to treatment that focuses on relieving pain. Yet, there was discordance between patients’ 
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reported preferred and actual roles in treatment decision making. Figure 3. When asked 
about their preferred role in decision making, 28% of TME patients preferred patient-
controlled decision making compared to 48% of LE patients (p=0.046). However, with 
regard to the treatment actually received, 38% of the TME group reported making their own 
surgical decision compared to 25% of the LE group (p=0.18).
Concerning patients’ beliefs, those who underwent LE were less likely than patients who 
underwent TME to report surgery “would likely cure their cancer” (63% vs. 80%, p= 0.04). 
Interestingly, for all patients who visited a radiation oncologist, the LE group was more 
likely to report that radiation would cure their cancer compared to the TME group, 63% vs 
27%, p=0.004. This difference in curative expectations was unchanged when comparing 
only patients that received radiation treatment.
Sensitivity Analysis
When we excluded older individuals (≥80 years old) and individuals with severe 
comorbidities, our key dependent variables did not change: patients’ preferred and actual 
decision-making roles. On subgroup analysis: when asked about preferred decision-making 
role, 29% of TME patients preferred patient-controlled decision-making compared with 47% 
of LE patients, p-value 0.02. With regard to the treatment actually received, 37% of TME 
group reported making their own surgical decision compared to 21% of the LE group, p-
value=0.15.
DISCUSSION
There are an increasing number of treatment options for patients with early stage rectal 
cancer. Very little is currently known about how physicians and patients decide on the best 
treatment options for patient. This study sought to address this gap in our understanding, and 
is among the first to explore surgical decision-making for rectal cancer treatment. We 
focused on the contrast between local excision and proctectomy, as studies have shown that 
transanal procedures are increasingly used in treatment of rectal cancer.1,19
In this population-based study of stage I rectal cancer patients, there was a discrepancy 
between reported preferred decision-making role regarding surgical treatment and reported 
actual decision-making role. Patients who underwent LE stated more frequently that they 
preferred to control the decision-making process; however this did not occur in as frequently 
in practice.
Untangling discrepancies between preferred and reported patient decision-making is 
challenging, as studies are limited.20 Prior studies focused in breast cancer have found 
matching patients’ preferred and actual roles increased patient satisfaction.21,22 Whether 
prior work in breast cancer is generalizable to colorectal cancer patients is unclear.23 An 
older study that measured preferred treatment decision-making in colorectal cancer patients 
found that the majority wanted to have a passive role in decision making.24 However this is 
in stark contrast to our findings, where the majority of patients preferred collaborative or 
active decision-making roles. We suspect this difference is due to a cultural shift in patient 
expectations regarding their role in care over time. Although we found a discrepancy 
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between reported preferred and actual decision-making roles, we did not find a difference in 
patient satisfaction with surgical care based on matched decision-making roles (results not 
shown).
Baseline patient characteristics may affect the surgical treatment offered to patients or 
selected. Older patients and those with more comorbidities may be steered away from TME. 
For this study, we did do a sensitivity analysis excluding the oldest and sickest patients. 
However, excluding these two groups did not influence the results for the patients’ preferred 
and actual roles in the decision-making process. Health literacy may also be an important 
factor in treatment decision-making.20 We did not find any difference in surgical treatment 
by education. In addition, while our study was unable to measure patient knowledge of 
specific treatment options, the LE group reported less frequently that surgery would cure 
their cancer than the TME group, which does provide some indication that patients 
understood the tradeoff of TME versus LE. At the same time LE patients were more likely to 
report radiotherapy as curative, which is inconsistent with medical teaching. Interestingly, a 
previous study showed patients more often reported the last treatment received as the 
curative treatment.25 While we were unable to assess the effects of temporality on patients’ 
perception of a treatment’s curative intent, this factor may have influenced our results.
We acknowledge there are many challenges to shared decision making with patients and in 
many cases this goal may be unrealistic. Often, it is not possible to fully inform patients who 
come in with limited knowledge about the treatment options yet have to make decisions that 
have major consequences. Furthermore, these difficult decisions are made at a time when 
patients are stressed with a new diagnosis of cancer and have only a short amount of time to 
review options with clinicians whom they have likely just met. Respecting patient 
preferences for control or involvement in clinical decisions while balancing our professional 
responsibility to use our expertise is one of the great challenges in clinical medicine today.26 
However, matching preferred to actual roles is important and will become increasingly 
relevant as we move toward more value-based care models and incentives based on 
outcomes, including patient-reported outcomes.27
The strengths of this study include factors that are inherent to CanCORS. The study cohort 
consisted of a population-based group of patients with rectal cancer from various geographic 
areas in the United States, and a robust set of variables, including information about 
decision-making, clinical factors including stage of disease, and follow-up data. 
Unfortunately, although CanCORS represented the largest existing population-based 
collection of incident colorectal cancer cases, the sample size is small due to the relative 
infrequency of early stage rectal cancer. This limited the ability to examine the impact of 
sociodemographic factors on preferred and actual decision-making roles. In addition, the 
response rate for this survey varied by question asked (range 68 – 94%). We do not know if 
the experiences of the respondents are representative of the experiences of the non-
respondents, so there is potential for nonresponse bias. This self-reported information may 
have been collected at any point within four months of diagnosis. Patients’ perceptions of 
the role they played in decision-making may evolve over that time period, resulting in recall 
bias.22 A patient’s perception about what they desired as a role or what role they actually 
played could be influenced by their experience with the treatment and morbidity or side-
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effects they could be experiencing. There were a large number of patients with Stage I rectal 
cancer receiving adjuvant therapy for a stage of disease traditionally treated by surgery only. 
It is possible that some of these patients were understaged by CanCORS. However, 
excluding patients with neoadjuvant therapy did not significantly change our results (not 
shown). Lastly and probably most importantly, we do not know what information was 
presented to patients with regard to options and provider recommendations for care.21
To further our understanding of patient decision-making, future work should focus on how 
sociodemographic factors, such as gender and age, influence decision-making role 
preference for this patient group. Additionally, future investigations should examine how 
surgeon-patient interactions may best foster patient understanding of the risks and benefits 
of treatment options.
In conclusion, this study reveals there is a mismatch between patients’ reported preferred 
and actual decision making roles for early stage rectal cancer. Matching roles in the 
decision-making process will add value to patients’ care received. Yet for complex decisions 
like the surgical treatment of early stage rectal cancer, providers must make sure patients are 
fully informed of the tradeoffs of treatment options, so we can empower each patient to 
make the best decisions possible.
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Figure 1. 
Patient’s Preferred Responses by Control Category
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Figure 2. 
Patients’ Actual Response Options by Control Category
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Figure 3. Patient Responses to Questions about Decision-Making Role Reported and Preferred 
by Patients
Shown are the responses of patients with stage I rectal cancer by surgical treatment type: 
total mesorectal excision (TME) or local excision (LE). Preferred role in the decision-
making process reported by patients (Panel I). Actual role in the decision-making process 
reported by patients (Panel II).
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Table 1
Unadjusted Associations of Patient and Institutional Characteristics by Surgical Treatment. a
Characteristic No. of Patients LE TME P-valueb
Overall No. of patients 154 32 (21%) 122 (79%)
Sex 154
 Female 12 (37%) 53 (43%) 0.55
 Male 20 (63%) 69 (57%)
Lives Alone 154 12 (38%) 40 (33%) 0.64
White ethnicity 154 25 (78%) 68 (56%) 0.02
Age group (years) 154
 <65 14 (44%) 65 (53%) 0.34
 ≥65 18 (56%) 57 (47%)
Comorbidities 154
 None/Mild 18 (56%) 98 (80%) 0.005
 Moderate/Severe 14 (44%) 24 (20%)
BMI 120
 <30 14 (56%) 81 (85%) 0.005
 ≥ 30 11 (44%) 14 (15%)
Education 145
 ≤12 years 11 (36%) 49 (43%) 0.45
 > 12 years 20 (65%) 65 (57%)
Insurance 154
 Covered by ≥ 1 payer 22 (69%) 79 (65%) 0.67
 None/Missing 10 (32%) 43 (35%)
Study Site 154
 HMO 6 (19%) 27 (22%) 0.88c
 Cancer Registry 21 (65%) 79 (65%)
 VA 5 (16%) 16 (13%)
Chemotherapy 154
 None 21 (65%) 86 (71%) <0.001c
 Pre-op 1 (3%) 31 (25%)
 Post-op 10 (32%) 5 (4%)
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Characteristic No. of Patients LE TME P-valueb
Radiotherapy 154
 None 22 (69%) 90 (74%) <0.001c
 Pre-op 1 (3%) 30 (24%)
 Post-op 9 (28%) 2 (2%)
Chemoradiotherapy 154
 Yes 10 (32%) 30 (24%) 0.44
 No 22 (68%) 93 (76%)
CES-D Short Form 103
 ≥ 6 0 (0%) 11 (13%) 0.12
 < 6 21 (100%) 71 (87%)
Survival 154
 Alive at 7 Years Post-Diagnosis 24 (77%) 88 (72%) 0.51
Abbreviations: TME, Total Mesorectal Excision; LE, Local Excision; BMI, Body Mass Index; HMO, Health Maintenance Organization, VA, 
Veterans Affairs; SD, standard deviation; CES-D, Center for Epidemiologic Studies Depression Scale
aUnless otherwise indicated, data are reported as number (percentage) of participants or decisions.
b
Pearson’s Chi-Square unless denoted by P-value
c
Fisher’s Exact Test
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